Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab.
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Rituximab
- Indications Burkitt's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.
- 09 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 09 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.